Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × GEN-1 × Clear all
NCT02480374 2024-10-02

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Imunon

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00473954 2013-03-26

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

EGEN, Inc.

Phase 1 Completed
13 enrolled
Gynecologic

Ovarian Neoplasms

NCT00137865 2013-02-28

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

EGEN, Inc.

Phase 1 Terminated
18 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡